QDEL · QuidelOrtho Corp
Market Cap
$958.00M
Shares
68.58M
QDEL metrics
71 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$13.97
Market cap
$958.00M
Price action
19 metricsPrice change (1W)
-5.2%
Price change (30D)
+13.7%
Price change (3M)
-2.5%
Price change (6M)
-32.9%
Price change (YTD)
-51.1%
Price change (1Y)
-49.7%
Trailing year
Price change (5Y)
-90.2%
52-week high
$35.38
52-week low
$9.96
Change from 52-week high
-60.5%
Change from 52-week low
+40.3%
Annualized volatility
89.4%
Beta
2.4
RSI (14D)
43.3
Price vs SMA 50
-12.5%
Price vs SMA 200
-28.2%
Avg volume (3M)
1.52M
Relative volume
0.6
Average dollar volume
$23.33M
Company
3 metricsSector
Healthcare
Industry
Medical Devices
Shares outstanding
68.58M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.4×
reciprocal yield 279.1%
P / book
0.5
reciprocal yield 185.3%
FCF yield
-22.0%
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-109.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.7×
reciprocal yield 58.4%
EV / revenue historical average (5Y)
1.8×
reciprocal yield 54.8%
EV / EBIT historical average (3Y)
27.3×
reciprocal yield 3.7%
EV / EBIT historical average (5Y)
27.3×
reciprocal yield 3.7%
EV / EBITDA historical average (3Y)
12.0×
reciprocal yield 8.4%
EV / EBITDA historical average (5Y)
12.0×
reciprocal yield 8.4%
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-06
Profitability
9 metricsGross margin
—
Operating margin
-30.8%
Trailing 12 months
Net margin
-39.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$824.70M
Net income (TTM)
−$1.05B
Trailing 12 months
Diluted EPS (TTM)
$-15.44
FCF margin
-7.9%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+2.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.67B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.9%
Year over year · more shares
Revenue CAGR (3Y)
-5.8%
Revenue CAGR (5Y)
+10.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-59.1%
Return on assets
-18.3%
Debt / equity
—
Current ratio
1.4
EBITDA (TTM)
−$370.50M
Free cash flow (TTM)
−$211.20M
Quick ratio
0.8
Interest coverage
-4.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$123.40M
Total assets
$5.72B
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$57.20M
Capital expenditures (TTM)
$154.00M
R&D (TTM)
$180.90M
SG&A (TTM)
$770.30M
Stock compensation (TTM)
$44.20M
R&D / revenue
6.8%
Stock compensation / revenue
1.7%
Ownership (13F)
3 metrics13F filers
249
13F filer change QoQ
+7
Institutional ownership
122.0%
Short interest
3 metricsShort interest
21.8%
Latest settlement · 7.6 days to cover
Days to cover
7.6d
Short-squeeze score
69 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1906324
CUSIP
219798105
13F (30d)
152 filings
152 filers
Visit website
Investor relations